Lenvima (Lenvatinib) for Endometrial Cancer

Overview
Lenvima is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) to be used with pembrolizumab for treating advanced endometrial cancer. It is meant for individuals whose cancer is mismatch repair proficient (pMMR, meaning their cells can fix certain DNA damage) or not microsatellite instability-high (MSI-H, meaning their cancer is less likely to respond to some immune therapies). This treatment is used when the disease has gotten worse after earlier treatments and surgery or radiation isn’t an option. Lenvima is also known by its drug name, lenvatinib.

Lenvima works by blocking specific proteins called kinases that help cancer cells grow and spread. When used with pembrolizumab, it helps the immune system find and attack cancer cells more effectively.

How do I take it?
Prescribing instructions say Lenvima is taken by mouth as a capsule. For endometrial cancer, the drug is taken once per day. It is taken with pembrolizumab, which is given as an intravenous (IV) infusion, meaning it is delivered directly into a vein, once every three weeks. Individuals should follow their health care provider’s instructions carefully when taking Lenvima.

Side effects
Common side effects of Lenvima include high blood pressure, fatigue, diarrhea, joint and muscle pain, decreased appetite, nausea, vomiting, mouth sores, weight loss, abdominal pain, urinary tract infections, constipation, headache, bleeding, rash, redness, itching, or peeling of the skin on your hands and feet, hoarseness, and rash.

Rare but serious side effects may include heart problems, arterial thromboembolic events (blood clots in arteries), liver damage, kidney failure, proteinuria (excess protein in urine), severe diarrhea, fistula formation (abnormal connections between organs), gastrointestinal perforation (holes in the stomach or intestines), QT interval prolongation (heart rhythm changes), hypocalcemia (low calcium levels), reversible posterior leukoencephalopathy syndrome (a rare brain condition), hemorrhagic events (bleeding), thyroid dysfunction (problems with thyroid hormones), impaired wound healing, osteonecrosis of the jaw (bone damage in the jaw), and embryo-fetal toxicity (harm to an unborn baby).

For more information about this treatment, visit:

Label: Lenvima — Lenvatinib Capsule;  Lenvima — Lenvatinib Kit — DailyMed